双胍类联合替莫唑胺在胶质母细胞瘤临床前模型中的生存影响:系统综述与Meta分析
该系统综述与Meta分析纳入9项研究,其中6项含85只大鼠模型(45只接受联合治疗),比较替莫唑胺联合双胍类与单用替莫唑胺对胶质母细胞瘤小鼠模型总生存期的影响;联合治疗组总生存期平均差为21.0天(95%CI 6.9-35.0)。
要点
- 替莫唑胺联合双胍类较单用替莫唑胺显著改善胶质母细胞瘤小鼠模型总生存期,平均差21.0天(95%CI 6.9-35.0)。
- 原位模型亚组联合治疗总生存期平均差23.7天(95%CI 6.5-40.9)。
- 二甲双胍亚组联合治疗总生存期平均差27.4天(95%CI 6.0-48.8)。
核心结论
- 该系统综述与Meta分析提供有力证据表明,在胶质母细胞瘤模型中,替莫唑胺联合双胍类较单用替莫唑胺显著改善总生存期。
研究设计与样本
- 系统检索Medline、Embase和Lilacs数据库,纳入比较替莫唑胺联合双胍类与单用替莫唑胺并报告总生存期数据的胶质母细胞瘤模型研究,采用随机效应模型计算平均差(MD)及95%置信区间。
- 系统综述纳入9项研究;Meta分析包含6项研究、85只大鼠模型,其中45只接受联合治疗。
主要发现
- 替莫唑胺联合双胍类组较单用替莫唑胺组总生存期显著更优,MD为21.0天(95%CI 6.9-35.0)。
- 原位模型亚组中,联合治疗组总生存期亦显著更优,MD为23.7天(95%CI 6.5-40.9)。
- 以二甲双胍作为双胍类治疗的亚组中,替莫唑胺联合二甲双胍组总生存期显著增加,MD为27.4天(95%CI 6.0-48.8)。
- 免疫缺陷模型亚组中,联合治疗组亦显示更高生存率,MD为13天(95%CI 9.4-16.6)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is an aggressive tumor known for its poor prognosis. Despite extensive research into its molecular and clinical aspects, the current management strategies have shown limited efficacy in improving survival rate. Despite some preclinical studies exploring the combination of temozolomide (TMZ) with biguanides such as metformin (MET) and others, the potential benefits of this combination remain uncertain. The aim of this study is to evaluate the overall survival (OS) in GBM murine-models treated with a combination of TMZ + biguanide compared to those treated with TMZ alone. METHODS: We systematically searched Medline, Embase, and Lilacs databases for studies comparing TMZ + biguanide versus TMZ alone in GBM models and reporting OS data. The mean difference (MD) with 95% confidence interval and random-effects model was adopted. RESULTS: Nine studies were included in this systematic review. The meta-analysis comprised 6 studies involving 85 rat-models, with 45 subjects undergoing combined-treatment. GBM-murine models treated with TMZ + biguanide exhibited notably superior OS rates compared to those who received TMZ alone, showing an MD of 21.0 days (6.9-35.0). Within the subgroup of orthotopic models, the OS was also significantly better in combination-therapy with an MD of 23.7 days (6.5-40.9). Similarly, in the subgroup where MET was used as biguanide therapy, TMZ + MET demonstrated a significant increase in OS, with an MD of 27.4 days (6.0-48.8). In immunocompromised models, the combination-therapy also exhibited higher survival rates, with an MD of 13 days (9.4-16.6). CONCLUSIONS: This systematic review and meta-analysis provide compelling evidence regarding the beneficial effects of TMZ + biguanide in GBM models compared with TMZ alone, resulting in a significant improvement in OS.
引用
- Ferreira MY, Thomaz de Assis EB, Batista S, et al. Survival Impact of Combined Biguanide and Temozolomide in Glioblastoma Preclinical Models: A Systematic Review and Meta-Analysis. World Neurosurg. 2024. PMID: 38184227. doi:10.1016/j.wneu.2024.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。